X4 Pharmaceuticals, Inc. (XFOR)
Largest Insider Buys in Sector
XFOR Stock Price History Chart
XFOR Stock Performance
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström …
Insider Activity of X4 Pharmaceuticals, Inc.
Over the last 12 months, insiders at X4 Pharmaceuticals, Inc. have bought $0 and sold $549,524 worth of X4 Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at X4 Pharmaceuticals, Inc. have bought $29,875 and sold $648,111 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 25,000 shares for transaction amount of $29,875 was made by WYZGA MICHAEL S (director) on 2023‑08‑18.
List of Insider Buy and Sell Transactions, X4 Pharmaceuticals, Inc.
| 2024-11-15 | Sale | President and CEO | 31,897 0.0186% | $0.39 | $12,583 | -3.05% | ||
| 2024-10-15 | Sale | President and CEO | 31,897 0.0161% | $0.56 | $17,926 | -8.48% | ||
| 2024-10-07 | Sale | President and CEO | 239,436 0.1183% | $0.55 | $131,522 | -1.79% | ||
| 2024-10-07 | Sale | Chief Operating Officer | 67,695 0.0345% | $0.57 | $38,329 | -1.79% | ||
| 2024-10-07 | Sale | Chief Scientific Officer | 76,920 0.0389% | $0.56 | $43,306 | -1.79% | ||
| 2024-10-07 | Sale | Chief Commercial Officer | 11,127 0.0059% | $0.58 | $6,506 | -1.79% | ||
| 2024-10-07 | Sale | Chief Financial Officer | 230,645 0.1141% | $0.55 | $126,901 | -1.79% | ||
| 2024-09-09 | Sale | Chief Operating Officer | 2,642 0.0016% | $0.66 | $1,738 | -17.45% | ||
| 2024-03-11 | Sale | President and CEO | 49,678 0.0287% | $0.88 | $43,856 | -16.72% | ||
| 2024-03-11 | Sale | Chief Operating Officer | 15,409 0.0089% | $0.88 | $13,591 | -16.72% | ||
| 2024-03-11 | Sale | Chief Scientific Officer | 14,235 0.0082% | $0.88 | $12,552 | -16.72% | ||
| 2024-03-11 | Sale | Chief Financial Officer | 52,500 0.0304% | $0.88 | $46,347 | -16.72% | ||
| 2024-02-12 | Sale | President and CEO | 21,695 0.0129% | $1.01 | $21,892 | -15.00% | ||
| 2024-02-12 | Sale | Chief Operating Officer | 3,683 0.0022% | $1.01 | $3,709 | -15.00% | ||
| 2024-02-12 | Sale | Chief Scientific Officer | 787 0.0005% | $1.01 | $793 | -15.00% | ||
| 2024-02-12 | Sale | Chief Financial Officer | 27,721 0.0165% | $1.01 | $27,973 | -15.00% | ||
| 2023-11-03 | Sale | President and CEO | 39,906 0.0231% | $0.90 | $35,915 | -11.18% | ||
| 2023-11-01 | Sale | President and CEO | 199,531 0.1172% | $0.73 | $145,658 | +11.79% | ||
| 2023-11-01 | Sale | Chief Operating Officer | 67,695 0.0398% | $0.73 | $49,417 | +11.79% | ||
| 2023-11-01 | Sale | Chief Scientific Officer | 67,695 0.0398% | $0.73 | $49,417 | +11.79% |
Institutional Investor Ownership
| Bain Capital Life Sciences Investors Llc | $23.51M | 10.07 | 16.92M | 0% | +$0 | 1.89 | |
| Nea Management Company Llc | $20.83M | 8.92 | 14.99M | 0% | +$0 | 0.1 | |
| BlackRock | $12.14M | 5.2 | 8.74M | +3.78% | +$442,496.77 | <0.0001 | |
| The Vanguard Group | $10.88M | 4.66 | 7.83M | -2.26% | -$251,781.81 | <0.0001 | |
| OrbiMed | $9.92M | 4.25 | 7.13M | 0% | +$0 | 0.08 |